Last reviewed · How we verify

Pred + Meth — Competitive Intelligence Brief

Pred + Meth (Pred + Meth) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Corticosteroid + Antimetabolite combination. Area: Immunology / Rheumatology.

phase 3 Corticosteroid + Antimetabolite combination Glucocorticoid receptor (prednisolone); Dihydrofolate reductase (methotrexate) Immunology / Rheumatology Small molecule Live · refreshed every 30 min

Target snapshot

Pred + Meth (Pred + Meth) — Hamad Medical Corporation. A combination of prednisolone (a corticosteroid) and methotrexate (an immunosuppressant/antimetabolite) that suppresses inflammation and immune activity.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Pred + Meth TARGET Pred + Meth Hamad Medical Corporation phase 3 Corticosteroid + Antimetabolite combination Glucocorticoid receptor (prednisolone); Dihydrofolate reductase (methotrexate)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Corticosteroid + Antimetabolite combination class)

  1. Hamad Medical Corporation · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Pred + Meth — Competitive Intelligence Brief. https://druglandscape.com/ci/pred-meth. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: